patient
neoplast
diseas
often
highli
suscept
sever
infect
follow
factor
influenc
type
sever
respons
therapi
infect
chang
epidemiolog
infect
cancerandor
treatmentassoci
neutropenia
acquir
immun
defici
state
cellular
immun
defect
recent
develop
newgener
diagnost
tool
includ
wide
avail
dna
amplif
test
effect
intervent
infect
prevent
empir
presumpt
therapi
highrisk
period
avail
new
class
highli
activ
antimicrobi
drug
strategi
promot
host
immun
respons
futur
measur
introductori
chapter
intend
reader
becom
familiar
import
histor
mileston
understand
develop
field
infecti
diseas
immunosuppress
patient
underli
neoplasm
patient
undergo
hematopoiet
stem
cell
transplant
patient
neoplast
diseas
often
highli
suscept
sever
infect
inclin
difficult
prevent
diagnos
treat
varieti
reason
discuss
detail
chapter
book
introduc
volum
review
histori
background
infect
believ
major
advanc
made
believ
necessari
effect
prevent
manag
infect
futur
follow
factor
influenc
type
sever
respons
therapi
infect
chang
epidemiolog
infect
cancerandor
treatmentassoci
neutropenia
acquir
immun
defici
state
cellular
immun
defect
recent
develop
newgener
diagnost
tool
includ
wide
avail
dna
amplif
test
effect
intervent
infect
prevent
empir
presumpt
therapi
highrisk
period
avail
new
class
highli
activ
antimicrobi
drug
strategi
promot
host
immun
respons
futur
measur
introduct
chemotherapeut
regimen
expand
popul
risk
sinc
mani
agent
affect
host
defens
often
caus
neutropenia
howev
even
acut
leukemia
malign
highest
frequenc
infect
littl
publish
infecti
complic
second
half
twentieth
centuri
pauciti
publish
data
illustr
book
acut
leukemia
publish
made
mention
infecti
complic
inde
time
physician
attribut
fever
leukemia
patient
gener
hypermetabol
condit
caus
neoplasm
sever
antineoplast
agent
becam
avail
caus
least
transient
improv
malign
diseas
nitrogen
mustard
caus
respons
hodgkin
diseas
aminopterin
caus
respons
acut
leukemia
methotrex
cure
choriocarcinoma
women
subsequ
use
multipl
drug
combin
acut
lymphocyt
leukemia
hodgkin
diseas
repres
major
advanc
anoth
import
advanc
use
platelet
transfus
control
prevent
hemorrhag
acut
leukemia
patient
thrombocytopenia
autopsi
studi
frequenc
hemorrhag
caus
death
acut
leukemia
patient
decreas
due
use
platelet
transfus
unfortun
infect
remain
major
caus
death
mani
review
subject
year
intern
contributor
continu
refer
surpris
frequenc
infect
relat
type
underli
malign
infect
occur
patient
fail
respond
cancer
therapi
survey
found
patient
acut
leukemia
lymphoma
less
patient
metastat
carcinoma
develop
infect
wide
varieti
factor
may
impact
suscept
cancer
patient
infect
local
factor
tumor
mass
may
obstruct
bronchial
tree
urinari
tract
necrot
tumor
gastrointestin
tract
result
infect
autopsi
studi
children
metastat
carcinoma
case
pneumonia
associ
pulmonari
metastas
aspir
tracheostomi
antibiot
therapi
often
limit
efficaci
type
tumor
unless
local
predispos
factor
remov
neutropenia
import
predispos
factor
due
diseas
therapi
report
role
neutropenia
infect
detail
analysi
patient
acut
leukemia
publish
studi
demonstr
risk
infect
relat
degre
durat
neutropenia
risk
increas
neutrophil
count
less
mm
increas
substanti
mm
also
risk
develop
infect
increas
longer
durat
neutropenia
one
hundr
percent
episod
sever
neutropenia
pmnml
last
week
longer
accompani
identifi
infect
compar
episod
last
one
week
neutropenia
diminish
likelihood
detect
characterist
manifest
infect
one
studi
compar
physic
find
infect
group
patient
sever
neutropenia
group
adequ
neutrophil
count
patient
former
group
pneumonia
abl
produc
purul
sputum
compar
latter
group
similarli
among
patient
urinari
tract
infect
pyuria
found
respect
autopsi
studi
demonstr
mani
pulmonari
infect
detect
routin
chest
radiograph
antemortem
likewis
among
patient
gramneg
bacillari
pneumonia
initi
abnorm
chest
radiograph
neutrophilsml
wherea
normal
roentgenogram
neutrophilsml
lack
sign
infect
febril
neutropen
patient
impair
physician
abil
determin
whether
fever
due
infect
one
studi
fever
neutropen
patient
physician
requir
conclud
whether
infect
present
institut
therapi
physician
initi
diagnosi
infect
fever
unknown
origin
incorrect
case
white
blood
cell
wbc
transfus
initi
effort
improv
outcom
infect
sever
neutropen
patient
sinc
difficult
collect
suffici
neutrophil
normal
donor
initi
patient
chronic
myelogen
leukemia
high
neutrophil
count
use
donor
later
develop
continu
cell
separ
machin
made
possibl
collect
adequ
cell
normal
donor
studi
demonstr
direct
relationship
number
cell
transfus
increment
recipi
neutrophil
count
one
studi
neutropen
patient
fever
unrespons
antibiot
therapi
respond
wbc
transfus
includ
patient
pneumonia
gramneg
bacillari
septicemia
unfortun
potenti
advers
effect
occur
recipi
one
studi
wbc
transfus
administ
amphotericin
b
patient
develop
acut
dyspnea
respiratori
deterior
new
pulmonari
infiltr
compar
patient
receiv
amphotericin
b
sever
studi
fail
observ
toxic
anoth
potenti
advers
event
primarili
bone
marrow
transplant
recipi
acquisit
cytomegaloviru
cmv
infect
report
graftversushost
diseas
gvhd
recipi
led
routin
irradi
transfus
cell
question
rais
advers
effect
radiat
function
transfus
neutrophil
review
seven
prospect
random
trial
wbc
transfus
neutropen
patient
infect
conclud
transfus
benefit
five
studi
number
patient
studi
small
problem
mani
ignor
number
neutrophil
administ
henc
patient
receiv
inadequ
dose
use
wbc
transfus
diminish
inadequ
evid
efficaci
prospect
compar
studi
howev
resurg
interest
increas
avail
neutrophil
sinc
recombin
myeloid
growth
factor
granulocytecolonystimul
factor
gcsf
becom
avail
administr
gcsf
donor
improv
number
neutrophil
collect
well
increas
activ
infect
protect
environ
risk
infect
period
chemotherapyinduc
neutropenia
effort
made
provid
steril
environ
patient
first
type
unit
bed
surround
plastic
canopi
filter
air
fig
later
laminar
air
flow
room
design
unit
provid
filter
air
steril
water
suppli
steril
room
special
prepar
food
toilet
facil
patient
given
specif
prepar
steril
food
prophylact
oral
topic
antibiot
room
air
food
patient
care
monitor
microbi
contamin
program
reduc
frequenc
infect
permit
use
intens
chemotherapi
premyeloid
growth
factor
era
unfortun
intens
chemotherapi
set
result
higher
remiss
rate
sever
malign
includ
acut
leukemia
lymphoma
sarcoma
one
review
protect
environ
entitl
protect
environ
discomfort
expens
offer
meaning
protect
summar
discuss
follow
one
constant
almost
everi
control
studi
life
prolong
remiss
induct
increas
remiss
prolong
late
earli
patient
neoplasm
origin
found
infect
organ
flora
nasopharynx
gastrointestin
tract
due
neutropenia
caus
diseas
subsequ
therapi
except
cellular
immun
defect
due
neoplasm
hodgkin
diseas
might
present
cryptococcosi
multipl
myeloma
might
present
pneumococc
septicemia
decreas
product
normal
immun
globulin
neutropen
patient
organ
invad
nasopharynx
usual
streptococcu
pyogen
staphylococcu
aureu
penicillin
suscept
orointestin
tract
escherica
coli
klebsiella
proteu
speci
respons
bacteria
sensit
avail
antibiot
earli
gradual
steadili
resist
develop
organ
except
pyogen
aureu
resist
penicillin
pseudomona
aeruginosa
resist
antimicrobi
except
polymyxin
appear
late
antimicrobi
resist
develop
year
among
orointestin
isol
gramposit
cocci
increas
becom
predomin
mrsa
penicillinresist
first
type
protect
environ
sever
neutropen
patient
note
sleev
side
canopi
perform
task
patient
chamber
foot
irradi
item
place
unit
alpha
streptococci
appear
mani
effect
anticanc
treatment
regimen
result
neutropenia
type
infect
remain
major
problem
patient
neoplast
diseas
contrast
patient
cellular
immun
defect
due
basic
diseas
therapi
prey
differ
array
organ
predispos
diseas
includ
hodgkin
diseas
lymphocyt
lymphoma
leukemia
hairi
cell
leukemia
variou
transplant
procedur
gvhd
along
treatment
includ
cyclosporin
antithymocyt
globulin
tacrolimu
adrenocorticosteroid
induc
defect
result
opportunist
infect
diseas
due
organ
categori
includ
salmonella
spp
histoplasma
capsulatum
leishmania
spp
cmv
earli
advent
aid
epidem
investig
access
laboratori
cell
could
measur
began
systemat
studi
reveal
patient
level
rang
lower
would
develop
one
opportunist
infect
especi
pcp
becam
appar
cell
fell
could
predict
organ
would
caus
diseas
measur
endogen
cytokin
tcell
subset
popul
function
analysi
even
predict
offer
opportun
treatment
prevent
bcell
defect
well
describ
occur
certain
group
patient
certain
underli
neoplast
diseas
multipl
myeloma
chronic
lymphocyt
leukemia
bone
marrow
transplant
instanc
organ
anticip
streptococcu
pneumonia
hemophilu
influenza
neiseria
meningitimu
late
transplant
echovirus
vaccin
studi
group
patient
other
underway
tri
achiev
protect
alter
integu
allow
access
larg
varieti
organ
invad
patient
neoplast
diseas
area
risk
includ
entir
orointestin
tract
chemotherapyinduc
mucus
ulcer
allow
organ
entri
tissu
bloodstream
intravascular
cathet
allow
direct
entri
bloodstream
cathet
bladder
intraperiton
intracrani
devic
sourc
infect
especi
neutropen
patient
addit
lifethreaten
infect
may
result
infus
blood
product
transplant
organ
may
vari
hiv
htlvi
salmonella
spp
candida
spp
trypanasoma
cruzi
among
other
know
immunolog
defect
patient
neoplast
diseas
suspect
infect
extrem
import
clinic
pictur
appropri
test
done
confirm
diagnosi
indic
empir
therapi
start
fine
exampl
empir
therapi
neutropen
patient
appropri
antibiot
anticip
organ
clinic
set
particular
hospit
earli
clinic
studi
nci
document
associ
fall
neutrophil
count
rise
sever
infect
exampl
popul
risk
specif
infect
due
immun
defect
prevent
pneumocysti
pneumonia
children
acut
lymphoblast
leukemia
carri
st
jude
hospit
memphi
tn
almost
protect
achiev
knowledg
perturb
immun
function
follow
bone
marrow
transplant
enabl
clinician
use
preemptiv
therapi
suspect
infect
caus
cmv
final
immun
defect
involv
innat
adapt
immun
respons
may
occur
patient
receiv
prolong
cours
chemotherapi
neoadjuv
antineoplast
monoclon
antibodi
therapi
immunosuppress
agent
treatment
gvhd
follow
allogen
stem
cell
transplant
remark
advanc
diagnost
test
evalu
infect
past
five
decad
especi
diagnost
microbiolog
allow
us
make
earlier
specif
microbi
diagnos
gram
stain
invent
han
christian
gram
denmark
variat
dye
techniqu
still
routin
use
earli
presumpt
diagnos
immunolog
method
use
direct
fluoresc
antibodi
stain
develop
regularli
use
especi
virus
unusu
circumst
suspect
polyoma
viru
infect
electron
microscopi
may
use
new
cultur
method
includ
isol
lysi
centrifug
tube
use
continu
aroundtheclock
monitor
employ
fluoresc
carbon
dioxid
detect
system
autom
broth
system
use
quantit
coloni
count
centrifug
sediment
system
sensit
isol
fungi
mycobacteria
bartonella
speci
addit
broth
examin
nucleic
acid
probe
hplc
rapid
organ
identif
autom
broth
minimum
inhibitori
concentr
mic
antimicrobi
suscept
test
yield
rapid
result
enter
onlin
comput
system
clinician
record
antimicrobi
suscept
pattern
hospit
infect
control
help
select
antimicrobi
regimen
empir
therapi
data
also
avail
local
nation
health
depart
well
hospit
polymeras
chain
reaction
pcr
techniqu
recogn
copi
nucleic
acid
fragment
variou
specimen
develop
use
mani
undergo
fda
approv
may
avail
special
laboratori
techniqu
may
well
replac
earlier
test
use
antigen
detect
poli
monoclon
antibodi
chemic
test
specif
cellular
element
arabinatol
beta
dglucan
galactomanan
fungi
antibodi
test
much
easier
perform
sinc
enzymelink
antibodi
elisa
test
replac
compliment
fixat
cf
test
specif
western
blot
becom
gold
standard
howev
cancer
patient
follow
allogen
stem
cell
transplant
serolog
diagnosi
may
provid
limit
inform
regard
activ
versu
remot
acquir
diseas
furthermor
neg
serolog
interpret
certainti
due
potenti
defect
bcell
function
radiolog
test
ct
scan
mri
better
defin
anatom
lesion
presumpt
diagnos
recent
advanc
safe
tissu
sampl
use
intervent
radiolog
techniqu
specif
diagnos
bronchoalveolar
lavag
virtual
replac
open
lung
biopsi
investig
pulmonari
lesion
howev
similar
diagnost
reliabl
serolog
diagnosi
neg
bal
sampl
smear
cultur
dose
exclud
possibl
opportunist
lung
infect
radioact
label
patient
neutrophil
inject
local
foci
infect
sometim
help
technetium
scan
effort
local
infect
site
use
antibodi
specif
organ
present
studi
method
could
also
offer
treatment
opportun
similarli
pet
scan
commonli
use
tumor
burden
diseas
recurr
monitor
new
technolog
appear
promis
adjuv
diagnost
tool
infect
occur
patient
nonhematolog
malign
caus
organ
commonli
associ
site
tumor
nosocomi
pathogen
except
chemotherapi
infect
patient
hematolog
malign
usual
caus
organ
preval
associ
specif
defici
host
defens
mechan
due
nosocomi
pathogen
exampl
present
discuss
primarili
focus
infect
preval
neutropen
patient
earli
studi
infect
patient
receiv
chemotherapi
hematolog
malign
found
aureu
develop
resist
penicillin
becam
predomin
caus
fatal
infect
neutropen
patient
effect
antibiot
becam
avail
treatment
penicillinresist
aureu
gramneg
bacilli
emerg
common
caus
fatal
infect
pseudonoma
aeruginosa
becam
major
caus
infect
especi
among
neutropen
patient
although
polymyxin
b
colistin
activ
vitro
pathogen
ineffect
therapi
neutropen
patient
limit
benefit
patient
efficaci
neutropen
patient
depend
upon
recoveri
neutropenia
avail
carbenicillin
first
b
lactam
antipseudomon
activ
dramat
impact
therapi
lifethreaten
pseudomona
infect
gramneg
bacilli
emerg
signific
pathogen
includ
klebiella
spp
serratia
marcescen
cephalothin
first
b
lactam
avail
treatment
infect
year
multipl
antibiot
develop
includ
potent
broadspectrum
cephalosprosin
carbapenim
fluoroquinolon
despit
import
advanc
bacteri
infect
remain
seriou
threat
cancer
patient
due
larg
part
abil
organ
develop
resist
multipl
antibiot
recent
increas
nonpseudomon
nonfer
gramneg
bacteria
stenotrophomona
maltophilia
associ
difficulttotreat
healthcareassoci
infect
bacteria
may
also
caus
less
sever
communityacquir
infect
highdos
trimethoprimsulfamethoxazol
remain
treatment
choic
although
occasion
multidrugresist
organ
pose
seriou
challeng
emerg
spread
extendedspectrum
betalactamas
esbl
enterobacteriacea
recent
identifi
carbapenemas
produc
klebsiella
speci
kpc
spread
gramneg
diseaseassoci
bacteria
herald
alarm
limit
choic
effect
antimicrobi
therapi
new
group
mdrgramneg
bacteri
infect
listeria
monocytogen
one
first
bacteri
infect
report
occur
frequent
patient
cellular
immun
defect
continu
problem
soon
becam
appar
salmonella
spp
nocardia
asteroid
rhodococcu
equi
also
opportunist
bacteri
pathogen
set
mycobacterium
hemphilum
thereaft
establish
mycobacterium
anticip
tcelldefici
patient
addit
classic
exampl
tubercul
subsequ
aviumintracellular
complex
discuss
limit
gener
principl
discuss
specif
antibiot
therapi
present
chapter
book
multipl
antibiot
becam
avail
potenti
emerg
resist
becam
appar
becam
standard
practic
withhold
antibiot
therapi
febril
patient
infect
pathogen
identifi
howev
earli
studi
antibiot
therapi
fever
neutropen
patient
clearli
indic
import
institut
antibiot
therapi
promptli
neutropen
patient
becom
febril
demonstr
mortal
rate
increas
substanti
therapi
administ
promptli
choic
initi
antibiot
therapi
provid
broadspectrum
antibacteri
coverag
gramposit
cocci
gramneg
bacilli
infect
caus
aerob
gramneg
bacilli
anaerob
infect
tend
uncommon
critic
import
physician
care
neutropen
patient
awar
common
pathogen
caus
infect
hospit
antimicrobi
suscept
appropri
antibiot
regimen
select
antibiot
bactericid
select
possibl
greatest
experi
obtain
broadspectrum
b
lactam
aminoglycosid
aminoglycosid
less
effect
singl
agent
neutropen
patient
use
alon
studi
indic
synergist
combin
provid
high
serum
cidal
level
b
lactam
plu
aminoglycosid
effect
singl
agent
howev
aminoglycosid
potenti
nephrotox
preval
elderli
patient
cancer
multipl
myeloma
cancer
therapi
induc
reduc
renal
reserv
variou
region
nation
intern
group
met
still
meet
studi
question
treatment
conduct
studi
evalu
treatment
bacteri
infect
includ
infecti
diseas
societi
america
european
organ
research
treatment
cancer
immunocompromis
host
societi
empir
antibacteri
treatment
evid
regimen
aim
preval
organ
reliabl
knowledg
suscept
infect
patient
given
hospit
must
stress
continu
effort
prevent
eg
scrupul
hygien
import
patient
fever
unknown
origin
persist
sever
day
broadspectrum
antibiot
therapi
repres
difficult
problem
care
reevalu
collect
addit
appropri
diagnost
test
need
perform
addit
therapeut
measur
consid
may
includ
antibacteri
antifung
antivir
agent
antifung
agent
given
seriou
consider
patient
investig
advoc
antibiot
therapi
continu
patient
document
infect
neutrophil
count
recov
consider
evid
indic
unnecessari
encourag
superinfect
appropri
approach
discontinu
therapeut
agent
watch
care
tubercul
wellrecogn
albeit
uncommon
complic
even
patient
sever
cellular
immun
defect
patient
solid
organ
cancer
may
suscept
activ
mycobacterium
tubercul
infect
patient
hematolog
malign
undergo
hematopoiet
stem
cell
transplant
remain
import
realiz
tubercul
indol
diseas
may
mistaken
slowli
progress
neoplasm
may
lead
unnecessari
larg
excis
avoid
initi
fine
needl
aspir
biopsi
suspect
mass
nontubercul
mycobacteri
diseas
due
slowgrow
mycobacteria
rise
cancer
patient
mycobacterium
intracellular
lung
infect
often
postmenopaus
women
select
defect
interferon
gamma
product
presenc
interferon
gamma
inhibitor
rapidli
grow
mycobacteri
rgm
lung
diseas
uncommon
mostli
seen
patient
undergo
chemotherapi
individu
perviou
pulmonari
involv
cancer
mycobacterium
chelona
mycobacterium
fortuitum
promin
rgm
associ
lung
diseas
recent
mycobacterium
abscessu
predomin
rgm
pulmonari
pathogen
abscessu
infect
difficulttotreat
due
high
level
drugresist
issu
relat
drug
intoler
patient
sever
cellular
immun
defect
significantli
poor
outcom
dissemin
rgm
endorgan
infect
except
mycobacterium
mucogenicum
catheterassoci
infect
respond
prompt
remov
infect
cathet
short
cours
combin
antimicrobi
therapi
fungal
infect
emerg
signific
complic
patient
hematolog
malign
effect
chemotherapi
becam
avail
major
predispos
factor
infect
determin
prolong
neutropenia
adrenocorticosteroid
therapi
interfer
macrophag
function
infect
also
preval
among
hsct
recipi
develop
graft
vs
host
diseas
receiv
adrenocorticosteroid
therapi
earli
increas
proport
patient
acut
leukemia
develop
fungal
infect
predominantli
candidiasi
aspergillosi
recent
year
infect
caus
zygomycet
fusrium
speci
scedasporium
speci
becom
increasingli
frequent
multipl
speci
candida
differ
antifung
suscept
pattern
infect
superfici
candidiasi
occur
cancer
patient
receiv
radiat
therapi
impair
tcell
function
infect
involv
oropharynx
esophagu
larynx
urinari
tract
gastrointestin
tract
serv
origin
dissemin
infect
especi
neutropenia
longterm
intraven
cathet
dissemin
infect
often
difficult
diagnos
may
sign
symptom
except
fever
progress
debilit
organ
often
cultur
blood
specimen
percent
patient
multipl
skin
lesion
chronic
form
dissemin
candidiasi
occur
neutropen
patient
persist
neutrophil
recoveri
character
persist
fever
debilit
weight
loss
patient
hepatosplenomegali
right
upper
quadrant
pain
mortal
rate
high
among
patient
treat
amphotericin
b
fluconazol
prophylaxi
associ
signific
increas
drugresist
candida
krusei
candida
glabrata
breakthrough
dissemin
infect
altern
lipid
formul
amphoterician
b
echinocandin
neutrophil
recoveri
critic
factor
recoveri
candidiasi
prolong
therapi
fluconazol
effect
chronic
candidiasi
recent
experi
suggest
antiinflammatori
agent
may
use
aspergillosi
major
site
infect
lung
sinus
dissemin
infect
uncommon
infect
acquir
inhal
spore
epidem
occur
construct
hospit
hypha
invad
blood
vessel
caus
thrombosi
infract
erod
facial
plane
cartilag
bone
patient
pulmonari
infect
may
present
symptom
suggest
acut
pulmonari
embol
characterist
nodular
infiltr
detect
pulmonari
ct
scan
halo
sign
radiograph
normal
cultur
specimen
often
neg
blood
galactamannan
test
help
establish
diagnosi
evalu
treatment
respons
sinu
infect
often
present
black
eschar
nose
palat
progress
infect
caus
proptosi
endophthalm
cerebr
infract
therapi
consist
effect
new
aspergillu
activ
triazolebas
drug
voriconazol
posaconazol
echinocandin
caspofungin
micafungin
combin
singl
agent
lipid
formul
amphoterician
b
also
use
combin
moldact
drug
neutrophil
recoveri
discontinu
system
immunosuppress
therapi
especi
adren
costicosteroid
import
recoveri
infect
surgic
resect
infect
tissu
may
benefit
patient
resect
residu
cavitari
lesion
may
necessari
prevent
pulmonari
hemorrhag
laterecur
bacteri
superinfect
patient
risk
develop
cryptococcosi
impair
cellular
immun
receiv
adren
corticosteroid
henc
patient
cll
lymphoma
hsct
recipi
greatest
risk
infect
acquir
inhal
organ
henc
lung
primari
site
infect
although
less
infect
patient
present
symptom
pneumonia
infect
progress
rapidli
lead
death
cancer
patient
develop
mening
wide
dissemin
infect
latex
agglutin
test
detect
cryptococc
antigen
cerebrospin
fluid
blood
infect
patient
optim
treatment
consist
initi
system
therapi
amphotericen
b
plu
lowdos
flucytosin
patient
mildtomoder
infect
highdos
oral
fluconazol
may
given
mainten
therapi
zygomycosi
caus
mold
order
mucoral
increas
frequenc
infect
share
characterist
aspergillosi
mortal
rate
exceed
despit
amphotericin
b
therapi
newer
azol
posaconazol
may
effect
therapi
trichosporon
infect
dissemin
organ
cultur
blood
specimen
patient
infect
includ
endophthalm
pneumonia
mening
osteomyel
optim
therapi
may
combin
amphotericin
b
fluconazol
mortal
rate
high
neutropen
patient
despit
therapi
highdos
voriconazol
may
effect
patient
dissemin
hepatosplen
trichosporon
speci
infect
breakthrough
trichosporon
infect
may
occur
patient
receiv
moldact
drug
echinocandin
oral
broadspectrum
triazol
fusarium
spp
caus
infect
predominantli
sinus
lung
fusariosi
like
aspergillu
speci
infect
angioinvas
pulmonari
nodular
masslik
diseas
indistinguish
mold
infect
infect
neutropen
patient
dissemin
organ
often
cultur
blood
specimen
nearli
half
patient
fungem
present
may
develop
multipl
nodular
skin
lesion
develop
necrot
center
skin
biopsi
diagnost
perform
promptli
mortal
remain
high
despit
avail
highli
activ
triazol
drug
organ
unresolv
immun
suppress
continu
influenc
treatment
respons
among
cancer
hematopoiet
stem
cell
transplant
hsct
recipi
system
fungal
diseas
variou
strategi
includ
donor
granulocyt
transfus
patient
sever
neutropenia
shown
signific
improv
outcom
recent
clinic
trial
combin
therapi
use
effect
antifung
agent
plu
recombin
cytokin
boost
macrophag
helper
cytotox
lymphocyt
function
explor
nonrandom
studi
use
granulocytemacrophag
colonystimul
factor
gmcsf
interferon
gamma
ifng
safe
appear
favor
impact
patient
receiv
donor
granulocyt
transfus
safeti
ifng
concern
due
potenti
cytokineinduc
graft
compromis
andor
gvhd
recipi
allogen
hsct
concern
observ
patient
lifethreaten
fungal
infect
although
larger
random
studi
need
explor
import
issu
similarli
drug
may
promot
pathogendirect
immun
captur
introduc
configur
chang
pathogen
explor
mani
year
littl
attent
focus
viral
infect
cancer
patient
due
lack
rapid
diagnost
test
effect
therapi
exampl
recent
year
commun
respiratori
viral
infect
recogn
potenti
seriou
immunocompromis
patient
tabl
list
viral
infect
avail
therapi
mani
acut
viral
infect
repres
reactiv
longstand
latent
infect
human
herp
virus
among
common
caus
viral
infect
cancer
patient
associ
signific
morbid
mortal
sever
immunocompromis
host
herp
simplex
virus
caus
oropharyng
esophag
diseas
may
dissemin
organ
reactiv
varicellazost
viru
occur
mainli
patient
leukemia
lymphoma
result
local
infect
shingl
dissemin
cutan
infect
pneumonia
enceph
hepat
small
bowel
diseas
cmv
infect
often
due
reactiv
latent
infect
also
attribut
transmiss
white
blood
cell
transfus
special
risk
hsct
recipi
may
receiv
infect
tissu
cmv
may
caus
hepat
meninoenceph
pneumon
gastroenter
diseas
immunosuppress
effect
increas
risk
infect
prophylaxi
preemptiv
therapeut
strategi
necessari
patient
undergo
stem
cell
transplant
epsteinbarr
viru
caus
fulmin
fatal
lymphoprolif
disord
occasion
patient
follow
allogen
stem
cell
transplant
immunocompromis
cancer
patient
occasion
develop
interstiti
pneumon
enceph
hepat
due
human
herp
viru
infect
progress
multifoc
leukoencephalopathi
demyelin
diseas
brain
caus
jc
viru
occur
infrequ
among
patient
cll
hodgkin
diseas
diseas
due
reactiv
latent
infect
preval
normal
adult
symptom
includ
visual
disturb
speech
defect
mental
deterior
lead
dementia
coma
patient
die
within
one
year
parvoviru
may
caus
anemia
cancer
patient
may
follow
sever
polyarthr
patient
infect
polyomaviru
bk
viru
persist
genitourinari
tract
major
caus
hemorrhag
cystiti
hsct
recipi
commun
respiratori
viral
infect
caus
respiratori
infect
cancer
patient
winter
spring
seriou
threat
transplant
recipi
patient
acut
leukemia
may
develop
viral
pneumonia
superinfect
bacteria
fungi
epidem
occur
transplant
leukemia
unit
patient
prolong
viral
shed
resolut
symptom
virus
caus
infect
includ
influenza
b
respiratori
syncyti
viru
rsv
parainfluenza
piv
adenoviru
stem
cell
transplant
recipi
follow
piv
rsv
infect
pulmonari
obstruct
defect
recent
recogn
may
sever
complet
resolut
may
take
longer
month
initi
viral
infect
novel
respiratori
virus
recent
recogn
caus
seriou
lifethreaten
diseas
includ
human
metapneumoviru
human
cornonaviru
agent
sever
acut
respiratori
syndrom
sar
human
bocaviru
adenoviru
also
caus
gastrointestin
infect
hepat
hemorrhag
cystiti
pancreat
enceph
fatal
dissemin
adenoviru
infect
seen
adult
pediatr
patient
profound
cellular
immun
defect
cordblood
transplant
recipi
gvhd
neurohepat
toxoplasosi
common
cancer
transplant
recipi
northeastern
unit
state
wherea
strongyloidiasi
infest
rate
mostli
seen
habit
southeast
southcentr
us
state
similarli
amebiasi
giardiasi
infrequ
seen
patient
rural
resid
consum
water
shallow
contamin
well
latent
toxoplasma
gondii
infect
difficult
diagnos
base
travel
food
consumpt
histori
domest
felin
exposur
serolog
may
diagnost
although
patient
bcell
defect
pcr
analysi
may
need
malaria
mostli
seen
patient
travel
endem
region
without
prophylaxi
receiv
ineffect
chemoprophylaxi
due
drugresist
strain
plasmodium
speci
airport
malaria
also
seldom
report
patient
resid
near
airport
frequent
intern
flight
transfus
malaria
observ
patient
neoplast
diseas
consid
explor
presenc
unexplain
fever
chaga
diseas
also
transmit
transfus
adult
tcell
leukemia
lymphoma
antineoplast
agent
like
cyclophosphamid
fludarabin
human
herpesviru
l
donovani
l
infantum
may
lead
seriou
viscer
leishmaniasi
l
donovani
seen
africa
asia
l
infantum
seen
africa
europ
mediterranean
central
south
america
vzv
rare
associ
system
dissemin
patient
humor
immun
defect
even
mix
immun
dysfunct
strongyloid
stercorali
may
lead
seriou
lifethreaten
hyperinfect
syndrom
patient
mark
cellular
immun
defect
caus
fever
pericardi
effus
diseas
may
becom
common
number
potenti
donor
come
endem
area
increas
also
reduvid
bug
appear
move
north
southwestern
state
screen
donor
may
becom
necessari
recent
increas
fatal
babesia
speci
infect
report
sinc
novemb
us
rais
concern
rare
intraerythrocyt
parasit
diseas
hydat
cyst
due
echinococcu
granulosu
e
multiloculari
neurocycticercosi
difficult
distinguish
cystic
brain
tumor
bacteri
fungal
brain
abscess
liver
hydrat
cyst
may
present
polymicrobi
bacteri
abscess
patient
develop
world
septicemia
includ
dissemin
infect
pneumonia
common
site
infect
urinari
tract
skin
central
nervou
system
infect
occur
less
commonli
site
infect
often
relat
site
primari
tumor
metastasi
surgic
procedur
septicemia
like
occur
patient
impair
host
defens
frequenc
infect
determin
sever
autopsi
studi
manag
pneumonia
cancer
patient
often
frustrat
difficult
spectrum
potenti
pathogen
except
broad
includ
infect
normal
host
occur
predomin
immunocompromis
host
predispos
factor
includ
defici
host
defens
mechan
neutropenia
hypo
igg
bronchial
obstruct
ulcer
due
tumor
mucos
damag
due
chemotherapeut
agent
use
mechan
ventil
cancer
patient
may
develop
pulmonari
infiltr
due
noninfecti
caus
hemorrhag
radiat
pneumon
leukoagglutinin
reaction
sever
neutropenia
patient
unabl
produc
adequ
inflammatori
respons
thu
may
fail
produc
persist
sputum
develop
clinic
sign
symptom
develop
abnorm
chest
radiograph
studi
gramneg
bacillari
pneumonia
cancer
patient
hematolog
malign
abnorm
radiograph
onset
pneumonia
never
develop
abnorm
identif
infect
pathogen
often
difficult
adequ
sputum
specimen
often
avail
diagnost
yield
invas
procedur
bronchoalveolar
lavag
suboptim
biopsi
often
contraind
risk
hemorrhag
due
thrombocytopenia
coagulopathi
use
ct
scan
blood
test
galactomannon
detect
aspergillosi
improv
diagnost
capabl
wide
varieti
infect
agent
may
infect
gastrointestin
tract
due
obstruct
ulcer
factor
discuss
focu
two
infect
potenti
seriou
consequ
neutropen
patient
typhliti
perian
infect
typhliti
neutropen
enterocol
character
welldemarc
ulcer
hemorrhag
larg
mass
organ
inflammatori
cell
usual
limit
cecum
extens
comput
tomographi
scan
provid
superior
imag
intraabdomin
organ
may
abl
diagnos
subclin
small
bowel
perfor
infect
collect
pneumatosi
intestinali
seriou
complic
requir
intens
bowel
manag
present
surgic
dilemma
bacteremia
occur
patient
therapi
consist
broadspectrum
antibiot
anticandida
agent
bowel
rest
decompress
import
perian
infect
common
patient
acut
monocyt
leukemia
promin
symptom
fever
pain
defec
lesion
often
aris
adjac
hemorrhoid
indur
ulcer
often
extens
necros
import
evalu
recrudesc
herp
viru
infect
perirect
abscess
evalu
surgic
intervent
may
obtain
prompt
respons
antimicrobi
therapi
drainabl
focu
identifi
cancer
patient
receiv
antineoplast
therapi
indwel
central
venou
access
cathet
infect
import
caus
delay
chemotherapi
hospit
cost
care
death
coagulaseneg
staphylococcu
con
skin
gramposit
bacteria
common
pathogen
cathet
remov
reduc
risk
infect
recurr
patient
highgrad
bacteremia
candidemia
without
hemodynam
compromis
cathet
remov
immedi
thorough
evalu
underli
endovascular
infect
septic
thrombophleb
may
yield
sourc
persist
bacteremia
lack
complet
respons
influenc
durat
system
antimicrobi
therapi
factor
influenc
antimicrobi
choic
includ
penetr
drug
biofilm
b
antimicrobi
activ
within
biofilm
c
activ
nonplankton
stationari
phase
microorgan
detail
discuss
import
topic
present
two
chapter
introductori
chapter
intend
reader
becom
familiar
import
histor
mileston
understand
develop
field
infecti
diseas
immunosuppress
patient
underli
neoplasm
patient
undergo
hematopoiet
stem
cell
transplant
